Cellular Biomedicine Group, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 13.366 million compared to USD 12.284 million a year ago. Net loss was USD 13.532 million compared to USD 12.096 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.63 a year ago. For the half year, sales was USD 0 compared to USD 49,265 a year ago. Operating loss was USD 24.797 million compared to USD 21.701 million a year ago. Net loss was USD 25.079 million compared to USD 21.433 million a year ago. Basic loss per share from continuing operations was USD 1.29 compared to USD 1.15 a year ago.